Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Canopy Growth Corporation due to allegations of violations of federal securities laws related to misleading statements and undisclosed costs impacting financial results [3][5]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Canopy Growth, with a deadline of June 3, 2025, for investors to seek the role of lead plaintiff [3]. - Investors who suffered losses from Canopy Growth between May 30, 2024, and February 6, 2025, are encouraged to discuss their legal options with Faruqi & Faruqi [1][3]. Group 2: Financial Performance and Allegations - The complaint alleges that Canopy Growth and its executives made false or misleading statements regarding the company's financial health, particularly concerning the costs associated with the Claybourne product launch and Storz & Bickel vaporizer devices [5]. - Canopy reported a gross margin decrease of 400 basis points to 32% in Q3 2025, primarily due to costs related to the Claybourne product launch and increased indirect costs [6]. - The company experienced a wider-than-anticipated loss of C$1.11 per share in Q3 2025, compared to the C$0.48 per share loss estimated by analysts [6]. Group 3: Market Reaction - Following the announcement of its financial results, Canopy's share price fell by $0.76, or 27.34%, closing at $2.02 per share on February 7, 2025 [8].

Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - Searchlight Resources Inc. (TSXV: SCLT) (OTC Pink: SCLTF) ("Searchlight" or the "Company") is pleased to announce that it has entered into an agreement with Canadian Gold Corp. (CGC) to option the Company's Flin Flon North project to CGC, for total compensation of $130,000 cash and $200,000 in CGC shares. The Flin Flon North project includes five claims covering 5,644.6 hectares, located 10 km north of Flin Flon, Manitoba (Map 1). The project i ...

Core Viewpoint - A class action lawsuit has been filed against Canopy Growth Corporation for alleged violations of federal securities laws, specifically regarding misleading statements about production costs and financial performance [1]. Group 1: Lawsuit Details - The lawsuit pertains to shareholders who purchased Canopy's securities between May 30, 2024, and February 6, 2025 [1]. - The complaint claims that Canopy Growth made false statements about significant production costs associated with the launch of Claybourne pre-rolled joints and vaporizer devices, which negatively impacted gross margin and overall financial performance [1]. - The company is accused of overstating the effectiveness of its cost reduction measures, leading to materially misleading public statements throughout the class period [1]. Group 2: Investor Participation - Shareholders who suffered losses during the specified class period are encouraged to contact the DJS Law Group to participate in the lawsuit [2]. Group 3: DJS Law Group Profile - DJS Law Group specializes in enhancing investor returns through securities class actions, corporate governance litigation, and M&A appraisals, representing large hedge funds and alternative asset managers [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Canopy Growth Corporation due to allegations of misleading statements and undisclosed costs that negatively impacted the company's financial performance [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that Canopy Growth and its executives violated federal securities laws by making false statements and failing to disclose significant costs related to the Claybourne product launch and Storz & Bickel vaporizer devices [4]. - Canopy reported a gross margin decrease of 400 basis points to 32% in Q3 2025, primarily due to costs associated with the Claybourne infused pre-roll launch and increased indirect costs related to vaporizer devices [5]. - The company experienced a wider-than-anticipated loss of C$1.11 per share in Q3 2025, compared to the C$0.48 per share loss estimated by analysts [5]. Group 2: Market Reaction - Following the announcement of the financial results, Canopy's share price fell by $0.76, or 27.34%, closing at $2.02 per share on February 7, 2025 [7]. Group 3: Legal Proceedings - Investors who purchased Canopy securities between May 30, 2024, and February 6, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and the June 3, 2025, deadline to seek lead plaintiff status in the class action [2][8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Canopy Growth Corporation securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Canopy Growth securities between May 30, 2024, and February 6, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 3, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that Canopy Growth made false and misleading statements regarding the costs associated with the launch of its Claybourne pre-rolled joints and the impact on its gross margins [5]. - It is claimed that the defendants overstated the efficacy of Canopy Growth's cost reduction measures while downplaying issues related to its financial health [5].

NEW YORK, May 30, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Canopy Growth Corporation (NASDAQ: CGC) between May 30, 2024 and February 6, 2025, both dates inclusive (the "Class Period"), of the important June 3, 2025 lead plaintiff deadline.So What: If you purchased Canopy Growth securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.What t ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

It may be time to sell Canopy Growth stock.Canopy Growth (CGC -20.76%) stock collapsed in morning trading Friday, down 20.5% through 11 a.m. ET after the company reported a comically bad earnings miss.Heading into today's report, analysts forecast the Canadian cannabis company would lose $0.20 per share in its fourth quarter of fiscal 2025. Instead, Canopy Growth reported a loss of (better sit down for this) $1.32 per share. Canopy Growth's gigantic Q4 missInvestors were not amused.Canopy management tried ...

Canopy Growth Corporation (CGC) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -840%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.76, delivering a surprise of -58.33%.Over the last four quarters, the company has ...

Revenue Performance - Canada cannabis revenue increased by 4% in Q4 FY2025 year-over-year, driven by a 13% growth in Canada medical cannabis[1] - Canada medical cannabis net revenue increased by 13% to $20 million in Q4 FY2025, while Canada adult-use cannabis net revenue declined by 3% to $20.4 million[17] - International markets cannabis net revenue decreased by 35% to $8 million in Q4 FY2025, primarily due to declines in Poland and Australia[12] - Canopy Growth Corporation reported a net revenue of CAD 65,031 thousand for the three months ended March 31, 2025, a decrease of 10.4% compared to CAD 72,788 thousand for the same period in 2024[52] - The Canada cannabis segment reported net revenue of CAD 40,377 thousand for the three months ended March 31, 2025, up from CAD 38,622 thousand in 2024, with an adjusted gross margin percentage of 11%[63] - For the year ended March 31, 2025, the Canada cannabis segment's net revenue was CAD 155,860 thousand, slightly down from CAD 159,165 thousand in 2024, but with an improved adjusted gross margin percentage of 25%[66] Financial Performance - Total debt was reduced by $293 million, or 49%, during FY2025, decreasing to $304 million as of March 31, 2025[1] - Adjusted EBITDA loss improved by 39% year-over-year to $9 million in Q4 FY2025, and by 60% to $24 million in FY2025[2] - Free cash flow outflow was $36 million in Q4 FY2025, a 60% increase in outflow compared to Q4 FY2024, while FY2025 outflow improved by 24% to $177 million[12] - Consolidated gross margin decreased by 500 basis points to 16% in Q4 FY2025, while adjusted gross margin decreased by 200 basis points to 19%[12] - The company experienced a net loss from continuing operations of CAD 604,138 thousand for the year ended March 31, 2025, compared to a net loss of CAD 483,682 thousand for the previous year, reflecting a 24.9% increase in losses[55] - The company reported a net loss from continuing operations of CAD 221,501 thousand for the three months ended March 31, 2025, compared to a loss of CAD 94,675 thousand in the same period of 2024, indicating a significant increase in losses[59] - Adjusted EBITDA for the three months ended March 31, 2025, was CAD (9,248) thousand, an improvement from CAD (15,091) thousand in the prior year[59] - Free cash flow for the three months ended March 31, 2025, was CAD (36,241) thousand, compared to CAD (22,709) thousand in the same period of 2024, reflecting increased cash usage[61] Asset and Liability Management - Total current assets decreased to CAD 294,574 thousand as of March 31, 2025, down from CAD 371,180 thousand as of March 31, 2024, representing a decline of 20.7%[48] - Canopy Growth's total liabilities decreased to CAD 430,488 thousand as of March 31, 2025, from CAD 799,823 thousand a year earlier, indicating a reduction of 46.1%[50] - The total assets of Canopy Growth Corporation decreased to CAD 917,701 thousand as of March 31, 2025, down from CAD 1,300,330 thousand as of March 31, 2024, a decline of 29.4%[48] - The company reported cash and cash equivalents of CAD 113,811 thousand as of March 31, 2025, a decrease of 33.2% from CAD 170,300 thousand at the end of the previous year[55] - Canopy Growth's inventory increased to CAD 96,373 thousand as of March 31, 2025, up from CAD 77,292 thousand a year earlier, reflecting a rise of 24.7%[48] Strategic Initiatives - Additional cost reduction initiatives are expected to deliver at least $20 million in annualized savings over the next 12-18 months[1] - The company aims to achieve positive adjusted EBITDA in the near term and positive free cash flow over time as it accelerates growth in global medical cannabis[2] - Canopy Growth is focused on expanding its presence in the U.S. cannabis market through Canopy USA, which includes ownership of Acreage and Wana, aiming to capitalize on growth opportunities[33] - The company anticipates growth in customer numbers and revenue, driven by new product offerings and market expansion strategies[43] - Canopy Growth is actively pursuing acquisitions, including the final tranche closing for Jetty, with an investment of up to $20 million from the Huneeus 2017 Irrevocable Trust[38] Operational Metrics - The company emphasizes the importance of Adjusted EBITDA as a key performance metric, which excludes various costs to provide a clearer picture of operational performance[27] - Free Cash Flow is highlighted as a critical measure for assessing liquidity, calculated as net cash from operating activities minus capital expenditures[28] - Adjusted Gross Margin and Adjusted Gross Margin Percentage are used to evaluate gross margin performance, excluding restructuring charges[29] Regulatory and Compliance - Canopy Growth is navigating regulatory uncertainties in the U.S. cannabis market, which may impact its business strategies and operations[36] - The company is focused on maintaining effective internal controls and ensuring compliance with financial reporting standards[41] - Future performance expectations are subject to various risks, including market conditions, competition, and regulatory changes[42] Cost Management - The company incurred acquisition, divestiture, and other costs of CAD 5,202 thousand for the three months ended March 31, 2025, down from CAD 13,062 thousand in the same period of 2024[59] - The company experienced a loss on asset impairment and restructuring of CAD 9,098 thousand for the three months ended March 31, 2025, compared to CAD 63,535 thousand in the same period of 2024[59]